

## CORRIGENDUM

# Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

J. Baselga, A. Manikhas, J. Cortés, A. Llombart, L. Roman, V. F. Semiglazov, M. Byakhov, D. Lokanatha, S. Forenza, R. H. Goldfarb, J. Matera, N. Azarnia, C. A. Hudis & M. Rozenzweig

*Ann Oncol* 2014; 25: 592–598 (doi: 10.1093/annonc/mdt543)

In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga:

JB is the consultant and on the advisory board for Roche and Novartis.